PROMACTA is indicated for the treatment of thrombocytopenia in adult and pediatric patients 1 year and older with chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Thrombocytopenia after a stem cell transplantation may signify an impending relapse, bone amrrow damage or viral infections. There are no sufficient prospective studies on t e use of Prmacta in this setting. A recent retrospective review by Yan et al concluded that: “despite the relatively good overall response rate to eltrombopag, inadequate platelet engraftment is a harbinger of poor outcome in allo-SCT.”
Yuan C et al, Eltrombopag for Treating Thrombocytopenia after Allogeneic Stem Cell Transplantation.Biol Blood Marrow Transplant. 2019 Jul;25(7):1320-1324
Tanaka T et al, Eltrombopag for Treatment of Thrombocytopenia after Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2016 May;22(5):919-24
Li S et al, Eltrombopag for Delayed Platelet Recovery and Secondary Thrombocytopenia Following Allogeneic Stem Cell Transplantation in Children.J Pediatr Hematol Oncol. 2019 Jan;41(1):38-41